Harrow (HROW) EBIT Growth (5y) (2015 - 2026)
Harrow (HROW) EBIT Growth (5y) (2015 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 43.94 Bn | 42.97 Bn | - |
| 2 | Teva Pharmaceutical Industries | 43.08 Bn | 39.43 Bn | 2.15 Bn |
| 3 | Zoetis | 31.54 Bn | 29.87 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.60 Bn | 22.80 Bn | 5.10 Bn |
| 5 | United Therapeutics | 22.12 Bn | 19.46 Bn | 683.80 Mn |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.50 Bn | 15.11 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 11.69 Bn | 11.16 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.13 Bn | 9.96 Bn | - |
| 10 | Harrow | 1.55 Bn | 1.47 Bn | 50.36 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -35.93% |
| Mar 31, 2026 | -57.10% |
| Dec 31, 2025 | 42.80% |
| Sep 30, 2025 | 55.98% |
| Jun 30, 2025 | 40.90% |
| Mar 31, 2025 | -78.03% |
| Dec 31, 2024 | 69.35% |
| Sep 30, 2024 | 18.13% |
| Jun 30, 2024 | 31.92% |
| Mar 31, 2024 | -65.62% |
| Dec 31, 2023 | -17.65% |
| Sep 30, 2023 | 36.20% |
| Jun 30, 2023 | 41.98% |
| Mar 31, 2023 | 21.79% |
| Dec 31, 2022 | -17.31% |
| Sep 30, 2022 | -15.07% |
| Jun 30, 2022 | 20.69% |
| Mar 31, 2022 | 20.08% |
| Sep 30, 2021 | 21.38% |
| Jun 30, 2021 | 20.47% |